Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
about
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerGenetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.Preoperative therapy for localized prostate cancer: a comprehensive overview.Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.Pharmacotherapeutic management of locally advanced prostate cancer: current status.A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy.Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review.Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.Prostate cancer: Developing novel approaches to castration-sensitive disease.Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary.Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins.Role of chemotherapy in prostate cancer.[Multimodal therapy of locally advanced prostate cancer].
P2860
Q27028084-2DA9E388-01BA-47A7-B153-E42FEDB80017Q30573750-17F46A8F-7ADD-4F92-A521-6F32741F2123Q34451219-AA94002A-2BA1-4B42-9027-F2AFBF995FBAQ37218730-0A095A30-5C56-409D-A195-391BBB0B26B0Q37354526-D42D66CE-89E5-4714-AC16-9EE8C405508CQ37463153-7D78DC37-19B7-47E3-B58E-D3326B9C8026Q37888666-65B2F879-68A3-48AD-9E3B-DCF963AB765DQ38014525-761C2AED-ADCE-416E-9022-5208E0ABE3BFQ38091071-D1DCE57B-9486-4DB6-8741-F33DA9FD14AFQ38185175-EFCFAB44-7989-4FA6-B264-65122D9F2B26Q38586993-3FB238AB-279C-468C-8FB6-AED839AE0D9BQ38801270-C7146972-1BB2-48CB-969A-5166BC21E798Q39356209-44200B62-9B89-4341-9DE0-3F167F15BD5FQ42486590-4E069961-79FB-4B74-8819-4E35B3044557Q50074875-3FB58C01-672F-46B6-A32B-9EEDFD3CF378Q52855360-82E35E6A-5F4E-4C45-93B9-58B4C9B0BAD0
P2860
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
@ast
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
@en
type
label
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
@ast
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
@en
prefLabel
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
@ast
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer
@en
P2093
Brooks L S Rademacher
Celestia S Higano
Ladan Fazli
Mark Garzotto
Nicole Janeba
Paul H Lange
Stephen Lieberman
Tomasz M Beer
P2860
P304
P356
10.1002/CNCR.24960
P407
P577
2010-04-01T00:00:00Z